Show simple item record

dc.contributor.authorSchlesinger, Tobias
dc.contributor.authorWeißbrich, Benedikt
dc.contributor.authorWedekink, Florian
dc.contributor.authorNotz, Quirin
dc.contributor.authorHerrmann, Johannes
dc.contributor.authorKrone, Manuel
dc.contributor.authorSitter, Magdalena
dc.contributor.authorSchmid, Benedikt
dc.contributor.authorKredel, Markus
dc.contributor.authorStumpner, Jan
dc.contributor.authorDölken, Lars
dc.contributor.authorWischhusen, Jörg
dc.contributor.authorKranke, Peter
dc.contributor.authorMeybohm, Patrick
dc.contributor.authorLotz, Christopher
dc.date.accessioned2021-04-06T09:29:30Z
dc.date.available2021-04-06T09:29:30Z
dc.date.issued2020-11-24
dc.identifier.citationPLoS One. 2020 Nov 24;15(11):e0242917. doi: 10.1371/journal.pone.0242917.en_US
dc.identifier.pmid33232382
dc.identifier.doi10.1371/journal.pone.0242917
dc.identifier.urihttp://hdl.handle.net/10033/622820
dc.description.abstractBackground: The viral load and tissue distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain important questions. The current study investigated SARS-CoV-2 viral load, biodistribution and anti-SARS-CoV-2 antibody formation in patients suffering from severe corona virus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS). Methods: This is a retrospective single-center study in 23 patients with COVID-19-induced ARDS. Data were collected within routine intensive care. SARS-CoV-2 viral load was assessed via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Overall, 478 virology samples were taken. Anti-SARS-CoV-2-Spike-receptor binding domain (RBD) antibody detection of blood samples was performed with an enzyme-linked immunosorbent assay. Results: Most patients (91%) suffered from severe ARDS during ICU treatment with a 30-day mortality of 30%. None of the patients received antiviral treatment. Tracheal aspirates tested positive for SARS-CoV-2 in 100% of the cases, oropharyngeal swabs only in 77%. Blood samples were positive in 26% of the patients. No difference of viral load was found in tracheal or blood samples with regard to 30-day survival or disease severity. SARS-CoV-2 was never found in dialysate. Serologic testing revealed significantly lower concentrations of SARS-CoV-2 neutralizing IgM and IgA antibodies in survivors compared to non-survivors (p = 0.009). Conclusions: COVID-19 induced ARDS is accompanied by a high viral load of SARS-CoV-2 in tracheal aspirates, which remained detectable in the majority throughout intensive care treatment. Remarkably, SARS-CoV-2 RNA was never detected in dialysate even in patients with RNAemia. Viral load or the buildup of neutralizing antibodies was not associated with 30-day survival or disease severity.en_US
dc.language.isoenen_US
dc.publisherPLOSen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleBiodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.en_US
dc.typeArticleen_US
dc.identifier.eissn1932-6203
dc.contributor.departmentHIRI, Helmholtz-Institut für RNA-basierte Infektionsforschung, Josef-Shneider Strasse 2, 97080 Würzburg, Germany.en_US
dc.identifier.journalPloS oneen_US
dc.source.volume15
dc.source.issue11
dc.source.beginpagee0242917
dc.source.endpage
refterms.dateFOA2021-04-06T09:29:30Z
dc.source.journaltitlePloS one
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Schlesinger et al.pdf
Size:
2.028Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International